AMR SVG Icons location

Hydroxyzine HCIInjection, USP


  • “AP” Rated and therapeutically equivalent to Vistaril®1*
  • Preserved with 0.9% Benzyl Alcohol
  • Vial closure is not made with natural rubber latex

Receive Availability Emails

  NDC# Strength Supplied As Shelf Pack Product Info Availability

25 mg/mL

1 mL
Single Dose Vial

0517-4201-25
0517-4201-25

25 mg/mL

1 mL
Single Dose Vial

25 In Stock
  • Shelf Pack 25
  • Availability In Stock

Wholesaler Numbers

  • ABC/SAP 10036541
  • Cardinal 1538560
  • HD Smith 5170543
  • McKesson 1622026
  • Morris & Dickson 076349

Case Information

  • Unit of Sale NDC 4201-25
  • Order Size 25
  • Case Size 40
  • Case Per Tier 108

50 mg/mL

2 mL
Single Dose Vial

0517-5602-25
0517-5602-25

50 mg/mL

2 mL
Single Dose Vial

25 In Stock
  • Shelf Pack 25
  • Availability In Stock

Wholesaler Numbers

  • ABC/SAP 10036552
  • Cardinal 1489251
  • HD Smith 5170428
  • McKesson 1784990
  • Morris & Dickson 076398

Case Information

  • Unit of Sale NDC 5602-25
  • Order Size 25
  • Case Size 40
  • Case Per Tier 108

50 mg/mL

1 mL
Single Dose Vial

0517-5601-25
0517-5601-25

50 mg/mL

1 mL
Single Dose Vial

25 In Stock
  • Shelf Pack 25
  • Availability In Stock

Wholesaler Numbers

  • ABC/SAP 10036560
  • Cardinal 1484682
  • HD Smith 5170550
  • McKesson 1622042
  • Morris & Dickson 076406

Case Information

  • Unit of Sale NDC 5601-25
  • Order Size 25
  • Case Size 20
  • Case Per Tier 198

*Vistaril® is a trademark of Pfizer Inc.
1Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/results_product.cfm?Appl_Type=A&Appl_No=087408. Updated February 2018. Accessed March 19, 2018.

Contact Us

Request a Grant Investigator Initiated Study Request a Certificate of Analysis Expanded Access Policy
Please choose your preferred method of contact
For Intramuscular Use Only INDICATIONS AND USAGE Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient.
2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens.
3. As pre-and postoperative and pre-and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis.
IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS Hydroxyzine hydrochloride intramuscular solution is intended only for intramuscular administration and should not, under any circumstances, be injected subcutaneously, intra-arterially or intravenously. Hydroxyzine is contraindicated in patients with a prolonged QT interval. This drug is contraindicated for patients who have shown a previous hypersensitivity to it. Because clinical data in human beings are inadequate to establish safety in early pregnancy, hydroxyzine is contraindicated in early pregnancy. WARNINGS Tissue damage: Intramuscular hydroxyzine hydrochloride may result in severe injection site reactions (including extensive tissue damage, necrosis and gangrene) requiring surgical intervention (including debridement, skin grafting and amputation). PRECAUTIONS: THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, BARBITURATES AND ALCOHOL. Rarely, cardiac arrests and death have been reported in association with the combined use of hydroxyzine hydrochloride intramuscularly and other CNS depressants. Therefore, when central nervous system depressants are administered concomitantly with hydroxyzine their dosage should be reduced up to 50 percent. HYDROXYZINE MAY POTENTIATE NARCOTICS AND BARBITURATES, so their use in preanesthetic adjunctive therapy should be modified on an individual basis.
When hydroxyzine is used preoperatively or prepartum, narcotic requirements may be reduced as much as 50 percent. Meperidine should be used with great caution and in reduced dosage in patients who are receiving other pre- and/or postoperative medications and in whom there is a risk of respiratory depression, hypotension, and profound sedation or coma occurring. Before using any medications concomitant with hydroxyzine, the manufacturer’s prescribing information should be read carefully.
Since drowsiness may occur with the use of this drug, patients should be warned of this possibility and cautioned against driving a car or operating dangerous machinery while taking this drug. CASES OF QT PROLONGATION AND TORSADE DE POINTES HAVE BEEN REPORTED DURING POSTMARKETING USE OF HYDROXYZINE. The majority of reports occurred in patients with other risk factors for QT prolongation or Torsade de Pointes (pre-existing heart disease, electrolyte imbalances or concomitant arrhythmogenic drug use). Therefore, hydroxyzine should be used with caution in patients with risk factors for QT prolongation, congenital long QT syndrome, a family history of long QT syndrome, other conditions that predispose to QT prolongation and ventricular arrhythmia, as well as recent myocardial infarction, uncompensated heart failure, and bradyarrhythmias. Caution is recommended during the concomitant use of drugs known to prolong the QT interval. Acute Generalized Exanthematous Pustulosis (AGEP)
Hydroxyzine may rarely cause acute generalized exanthematous pustulosis (AGEP), a serious skin reaction characterized by fever and numerous small, superficial, nonfollicular, sterile pustules, arising within large areas of edematous erythema. Inform patients about the signs of AGEP. Discontinue hydroxyzine at the first appearance of a skin rash, worsening of pre-existing skin reactions which hydroxyzine may be used to treat, or any other sign of hypersensitivity. If signs or symptoms suggest AGEP, use of hydroxyzine should not be resumed and alternative therapy should be considered. Avoid cetirizine or levocetirizine in patients who have experienced AGEP or other hypersensitivity reactions with hydroxyzine, due to the risk of cross-sensitivity.
ADVERSE REACTIONS
Therapeutic doses of hydroxyzine seldom produce impairment of mental alertness. However, drowsiness may occur; if so, it is usually transitory and may disappear in a few days of continued therapy or upon reduction of the dose. Dryness of the mouth may be encountered at higher doses.
Involuntary motor activity, including rare instances of tremor and convulsions, has been reported, usually with doses considerably higher than those recommended. Hydroxyzine hydrochloride is associated with Acute Generalized Exanthematous Pustulosis (AGEP) in post-marketing reports. For additional Safety Information, please see Full Prescribing Information. You are encouraged to report Adverse Drug Events (ADEs) to American Regent Inc. at 1-800-734-9236 or to the FDA by visiting www.fda.gov/MedWatch or calling 1-800-FDA-1088.